Toronto Metropolitan University
Browse
90423a57af4d080dee42f0f27089722c.pdf (12.57 MB)

The Synthesis of Molecular Probes Based on Cystic Fibrosis Drugs for Biological Research

Download (12.57 MB)
thesis
posted on 2024-03-18, 17:04 authored by Philip Junor

Cystic fibrosis (CF) is a genetic disorder caused by a mutation in the gene that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. These mutations either impair trafficking to thecell membrane, reducefunction as ananion channel,orboth. Ivacaftor(a channel potentiator) was the first FDA-approved drug that treats the underlying cause of CF, specifically for patients with the G551D mutation. Shortly after, Orkambi, a combination of ivacaftor and the trafficking corrector lumacaftor was FDA-approved for patients homozygous for the F508del mutation. Based onclinical studies, itisreportedthatOrkambi has amodesteffect onlung function due to the negative impact of ivacaftor on the stability of F508del CFTR. Ivacaftor and lumacaftor were discovered and optimized through functional bioassays, and their interaction at the molecular level is not fully understood. To better understand the drug-protein interaction and inform the development of better CF drugs, molecular probes have been synthesized based on the structures of ivacaftor and lumacaftor.

History

Language

eng

Degree

  • Doctor of Philosophy

Program

  • Molecular Science

Granting Institution

Ryerson University

LAC Thesis Type

  • Dissertation

Thesis Advisor

Russell Viirre

Year

2022

Usage metrics

    Molecular Science (Theses)

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC